Nephrocare Health Services

    NEPHROPLUS
    Pharma
    ₹653.00
    Price as of 18 Nov 2026, 9:58 pm IST

    Market cap ₹6,567 Cr

    P/E
    53.57
    Day range
    ₹648.40 – ₹690.95
    52-week range
    ₹446.00 – ₹781.50
    Volume
    3.39 L
    Open
    ₹663.35
    Prev close
    ₹667.75

    Latest results · Q2 FY27(consolidated)Revenue ₹303 CrProfit ₹34 CrMargin 11.1%YoY vs the same quarter last year

    1 red flag to read up on

    • medium

      Promoter holding falling

      58.31%, down 5.54 pts since 2025-12-16 · 30 Sept 2026

    From NSE and BSE filings. A flag is a reason to read the filing, not a rating.

    Research profile

    Composite 54 / 100

    Factor percentiles

    Value41
    Quality50
    Momentum55
    Low volatility69

    Derived metrics

    Earn. yield
    1.9%
    Graham no.
    ₹185.47
    vs Graham
    -71.6%
    ROE ÷ P/B
    1.7%
    Magic Formula
    #478
    FCF yield
    1.7%

    Percentiles rank this stock against the other tracked stocks and change as they do. Scans describe where figures sit today. Hover a label for its definition. Not investment advice.

    Peer comparison

    All 68 in Pharma
    Largest Pharma companies tracked, with sector medians
    CompanyM-capP/EP/BROEROCEOPMD/ESales YoY
    Sun PharmaSUNPHARMA₹4.49 L Cr40.955.0314.8%21.0%29.0%0.04+11.9%
    Divi's LaboratoriesDIVISLAB₹2.93 L Cr87.1916.8816.2%22.0%43.0%0.00+35.4%
    Torrent PharmaTORNTPHARM₹1.75 L Cr77.889.6726.8%15.0%33.0%0.77+50.8%
    Apollo HospitalsAPOLLOHOSP₹1.27 L Cr56.4011.5522.6%17.0%16.0%0.77+23.0%
    Laurus LabsLAURUSLABS₹1.25 L Cr93.7219.8218.2%18.0%34.0%0.43+33.5%
    Zydus LifesciencesZYDUSLIFE₹1.20 L Cr28.724.3220.1%21.0%24.0%0.50+29.2%
    Dr. Reddy's LabsDRREDDY₹1.17 L Cr41.632.9711.6%13.0%20.0%0.19-1.5%
    Nephrocare Health ServicesNEPHROPLUS₹6,567 Cr53.575.449.1%15.0%21.0%0.13+23.2%
    Sector median₹24,603 Cr43.685.4615.1%17.0%24.0%0.17+22.7%

    Sector as classified in the tracked universe; medians use every tracked Pharma company, and P/E only profitable ones. Tinted figures beat the median.

    Latest news

    Updated 1h ago

    Headlines about Nephrocare Health Services from the last two weeks in the financial press. Stories belong to their publishers; Rajat Finance does not endorse them.

    Key metrics

    P/E (TTM)
    50.4
    Price / Book
    5.53
    ROE (FY26)
    9.1%
    ROCE (latest year)
    15%
    Dividend yield
    0.00%

    Moving averages (NSE)

    20-day
    ₹624.21
    Price above
    50-day
    ₹659.57
    Price below
    200-day
    ₹625.82
    Price above

    Charts & trends

    From company filings. Amounts in ₹ crore.

    Revenue 3Y CAGR
    +31.7%
    Revenue YoY (Sep 2026)
    +23.2%
    Operating margin
    21.0%
    Net margin
    11.2%

    Revenue, profit & margin - quarterly

    ₹ crore; a loss shows red. Operating margin below, same periods.

    -100 Cr0 Cr100 Cr200 Cr300 Cr400 Cr
    • Revenue
    • Net profit

    Operating margin

    Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 20260%15%30%

    Who owns the company

    % of equity by quarter, latest Sept 2026

    Dec '25Mar '26Jun '26Sept '260%25%50%75%100%
    • Promoter
    • Public
    • FII
    • DII

    Cash flows

    Where cash came from and went, by fiscal year (₹ crore)

    Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026-400 Cr-200 Cr0 Cr200 Cr400 Cr
    • Operating
    • Investing
    • Financing
    • Free cash flow

    Return on equity

    Net profit over shareholders' equity, by fiscal year

    FY22FY23FY24FY25FY26-10%0%10%20%15% screen

    Equity vs debt

    Shareholders' equity against borrowings (₹ crore); the ratio below, same years.

    0 Cr500 Cr1K Cr1.5K Cr
    • Equity
    • Debt

    Debt to equity

    Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Sep 20260x0.5x1x

    Financial statements

    ₹ Crore
    Quarterly results, oldest period first, figures in rupees crore
    Line itemDec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
    Sales197219228246260266282303
    Expenses153168180182199215221240
    Operating Profit4451486461516063
    OPM %22%23%21%26%23%19%21%21%
    Other Income547431278
    Interest566456323
    Depreciation1819202322262528
    Profit before tax263029-136334140
    Tax %24%17%17%1427%11%9%22%17%
    Net Profit202524-932303234
    EPS in Rs₹2.17₹2.68₹2.56₹-1.02₹3.21₹3.03₹3.19₹3.33

    From company filings, updated 17 Nov 2026. Consolidated figures where the company reports them. Information only, not investment advice.

    Working-capital cycle

    Debtor Days116

    +15 days since Mar 2021

    Inventory Days67

    +2 days since Mar 2021

    Days Payable63

    +7 days since Mar 2021

    Cash Conversion Cycle116

    +6 days since Mar 2021

    Working Capital Days42

    +16 days since Mar 2021

    Strengths, risks & growth

    Incorporated in 2010, Nephrocare Health Services Ltd. provides end-to-end dialysis care through a wide network of clinics across India and select international markets. [1]

    Strengths

    • Company has reduced debt.
    • Company has delivered good profit growth of 162% CAGR over last 5 years

    Risks

    • Stock is trading at 5.43 times its book value
    • Though the company is reporting repeated profits, it is not paying out dividend
    • Promoter holding has decreased over last quarter: -5.53%
    • Company has a low return on equity of 10.2% over last 3 years.

    Compounded Sales Growth

    10 Years
    —
    5 Years
    +28%
    3 Years
    +32%
    TTM
    +25%

    Compounded Profit Growth

    10 Years
    —
    5 Years
    +162%
    3 Years
    +103%
    TTM
    +116%

    Return on Equity

    10 Years
    —
    5 Years
    +6%
    3 Years
    +10%
    Last Year
    +9%

    Strengths and risks are a machine-generated checklist, not advice; growth is compounded annually over each period.

    Shareholding pattern

    Percentage of shares held by each category at each quarter end
    HolderDec 2025Mar 2026Jun 2026Sept 2026Change
    Promoter63.85%63.85%63.85%58.32%-5.53 pp
    FII9.30%9.94%8.78%11.73%+2.95 pp
    DII8.10%8.64%9.05%8.11%-0.94 pp
    Public18.74%17.56%18.30%21.85%+3.55 pp

    Filed with NSE for Sept 2026: promoters 58.31%, public 41.69%

    Analysts & fund holdings

    100%
    100% recommend buy
    5 analysts cover the stock
    Valuation vs Health Care Providers & Services
    P/E53.6 vs 45.2
    Sector P/B6.05

    Who holds the shares, quarter by quarter

    Mutual funds 3.93% (+0.73 pp)
    Jul 25
    Dec 25
    Mar 26
    Jun 26
    Sept 26
    • Promoters58.3%
    • Foreign institutions11.7%
    • Mutual funds3.9%
    • Insurance0.5%
    • Other domestic institutions3.7%
    • Retail6.4%
    • Others15.4%
    Mutual funds holding the most
    Fund% of company% of fund3-month change
    SBI Healthcare Opp Fund0.92%1.01%-0.19 pp
    DSP Healthcare Fund0.60%1.05%-0.14 pp
    Bandhan Innovation Fund0.41%0.84%+0.84 pp
    Bandhan Small Cap Fund0.39%0.07%+0.07 pp
    LIC MF Infra Fund0.38%2.24%+2.24 pp

    Scorecard

    Performance
    Low
    Valuation
    High
    Growth
    Low
    Profitability
    High
    Entry point
    Good
    Red flags
    Low

    Analyst coverage, holdings and scorecard from market data; not a recommendation by Rajat Finance.

    Risk & trend

    From 226 daily sessions to 18 Nov 2026.

    Computed

    Risk

    Volatility (1Y)
    40.4%
    Downside volatility
    34.7%
    Worst 5% of days
    4.0%
    Average of that tail
    4.8%
    Max drawdown (1Y)
    22.1%
    Below its peak
    14.7%

    Against the market

    Beta vs Nifty 50
    0.59
    Correlation
    0.22
    Relative strength (3M)
    -9.9%
    ATR (14)
    3.9%

    Return

    Return 1M
    +6.3%
    Return 3M
    -6.0%
    Return 6M
    +1.4%
    Return 1Y
    —
    vs 200-day average
    +4.3%

    Momentum

    RSI (14)
    55.6
    MACD histogram
    7.43
    Stochastic %K
    64.0
    ADX (14)
    27.1
    +DI / −DI
    26.3 / 15.8
    Money flow index
    50.4

    Participation

    Delivery (20d avg)
    47.8%
    vs its 60-day baseline
    -4.9 pts
    Volume vs 20-day
    +2.1σ
    Close vs day's VWAP
    -2.9%
    52-week position
    64 / 100

    These describe what this stock's price has already done. They are not forecasts, signals or recommendations, and a dash means the figure was withheld for want of enough history rather than being zero.

    Financial quality

    From consolidated statements to 30 Sept 2026.

    Computed

    No F-Score: it needs two reporting periods a year apart that carry both an income statement and a balance sheet, and this company's filings do not yet line up that way. The ratios below need only the one period and are unaffected.

    Free cash flow
    ₹113 Cr
    FCF yield
    1.7%
    Net debt
    -₹64 Cr
    Net debt / equity
    -0.05
    EV / sales
    5.86

    Computed from filed statements, not filed themselves. A dash means an input was absent, and the score counts only the criteria that could actually be tested.

    Corporate actions

    No dividends, splits or bonuses recorded for this company yet.

    Company announcements

    Company Update
    Disclosure Under Regulation 30 Of The SEBI Listing Regulations - Grant Of Esops Under The Nephroplus Employee Stock Option Scheme 2026.

    We hereby inform that the Company has approved grant of ESOPs under the Scheme as per the disclosure annexed herewith.

    Company Update
    Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

    Pursuant to Reg 30 of SEBI Listing Regulations, 2015, we hereby inform that the Company has approved allotment of 3,42,130 equity shares of Rs. 2/- each, pursuant to the exercise of stock ....

    Company Update
    Announcement under Regulation 30 (LODR)-Earnings Call Transcript

    Please find enclosed herewith Transcripts for the Investors Earnings call held on November 4, 2026.

    Company Update
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    Pursuant to Reg 30 of the SEBI Listing Regulations, we hereby inform you that the Company has scheduled an investor conference call as per the disclosure annexed herewith.

    Company Update
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

    In Continuation to our letter dated October 21, 2026 please find enclosed link of the audio recording of the Investors' Conference Call held on November 04, 2026 on the Unaudited Standalone ....

    Company Update
    Announcement under Regulation 30 (LODR)-Monitoring Agency Report

    Please find attached monitoring agency report for the quarter ended September 30, 2026.

    Company Update
    Announcement under Regulation 30 (LODR)-Investor Presentation

    Please find investor presentation for quarter and half year ended September 30, 2026.

    Company Update
    Announcement under Regulation 30 (LODR)-Press Release / Media Release

    Press release on Unaudited standalone and consolidated financial results for quarter and half year ended September 30, 2026.

    Board Meeting
    Board Meeting Outcome for Outcome Of The Board Meeting Held On November 3, 2026.

    Outcome of the Board meeting held on November 3, 2026 for considering and approving the financial results for the period ended September 30, 2026.

    Company Update
    Disclosure Under Regulation 30 Of SEBI Listing Regulations

    Pursuant to Reg 30 of SEBI Listing Regulations, we wish to hereby inform that the tax assessment order against the Company's overseas wholly-owned subsidiary has been declared invalid ....

    Company Update
    Announcement under Regulation 30 (LODR)-Memorandum of Understanding /Agreements

    Pursuant to Reg 30 of SEBI Listing Regulations, we hereby inform you that Nephrocare Health Services, Philippines Inc., a step-down wholly owned subsidiary of the company has acquired a ....

    Company Update
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    Pursuant to Reg 30 of the SEBI Listing Regulations, we hereby inform you that the Company has scheduled an investor conference call as per the disclosure annexed herewith.

    Board MeetingPrice-sensitive
    Board Meeting Intimation for Consideration And Approval Of The Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter And Half Year Ended September 30, 2026.

    Nephrocare Health Services Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/11/2026 ,inter alia, to consider and approve the Unaudited Standalone ....

    Company Update
    Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    We are enclosing herewith a certificate under Reg 74(5) of SEBI (DP) Regulations, 2018 for quarter ended 30th September, 2026 received from M/s. KFIN Technologies Limited.

    Insider Trading / SAST
    Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

    The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Polar Capital Funds PLC

    Filed with BSE (scrip 544647); the last 45 days. Documents open at bseindia.com.

    Documents

    Credit ratings

    Documents open at BSE or the rating agency that issued them.

    Sourced from the company's NSE XBRL filing dated 4 Nov 2026 (unaudited). View the source filing. Figures are as filed and are not investment advice.

    FAQ

    Nephrocare Health Services: common questions

    Answered from the figures on this page.

    Nephrocare Health Services last traded at ₹653.00 (NSE, as of 18 Nov 2026). The last session moved it down 2.21%.

    Nephrocare Health Services is valued at about ₹6,567 crore (NSE, as of 18 Nov 2026).

    Nephrocare Health Services trades at a price-to-earnings ratio of 53.57 (NSE, as of 18 Nov 2026). The P/E compares the share price with earnings per share, so it is only comparable between companies in the same industry.

    Nephrocare Health Services has traded between ₹446.00 and ₹781.50 over the past 52 weeks, to 18 Nov 2026. It is currently 62% of the way up that range.

    Nephrocare Health Services (NEPHROPLUS) is classified under Pharma on this site's screener.